Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
more upside now than downside
Recs
I'm always a little late to the dip with Alexion because I can't shake the worry that they'll get the rug pulled out from under them a la Questcor. Their 18B market cap seems unimaginably large for a company that sells a single product to treat a rare disease. Most recently, I had the stock flagged for a green thumb at 85 and a real buy at ... probably never. But Portefeuille made it easy for me by directing a 100 share buy at 90.32 for the collaboration. Making real money on Alexion will make a nice counterpoint to have been pummeled by the stock on CAPS.
Recs
expensive on all valuations
Recs
best drug for what it heals
Recs
jim cramer likes it
Recs
It was picked by www.hechtsoft.de Trade Alerts.
Recs
After a 60% run-up, this volatile stock seems due for a fall. TM P/E of 82.96 with expected earnings growth of 31.54% taking it to a forward P/E of 38.81 next year. ALXN also trades at a premium to S&P500 TTM P/E. The PEG stands at 2.24, this could suggest some overvaluation. The Price/Book is 11.62.
Recs
just following the trend...
Recs
Increasing sales and margins screen. (master list).
Recs
soaring to the moon!!
Recs
The long-term potential growth for this company is astronomical... They seem to have incredible moment at this point, and is closely linked to stock-market turbulence. Very excited for this companies potential, and am buying in for the long hall.
Recs
Generic dtugs
Recs
Recs
Found this stock with a screen that looks for stocks that are stratospherically valued based on high expectations. CAPS score of 2 is higher than expected, which indicates that somebody likes this stock at this price. The deciding factor for me was the negative commentary from ZZLangerhans.
Recs
biotech spec 3
Recs
Upcommimg biotech with a first in class drug due to expand its fda indications. They have pricing power, an off the beaten path pipeline, international presence and good marketing reach in the US. They face no competition for their indications, think Genzyme, only more focused. Could be an acquisition too.
Recs
Russell 2000 long term growth 31-173%
Recs
earnings
Recs
eps is growing rapidly. good roe.
Recs
All you need to do is wait, Japan will be on board in 2010. Earnings will just keep growing for the next two years. No matter the economy. During this time just relax and wait for the stock to go up.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 35 : 1 2 Next »